360° Coverage : Genapsys, Inc. Raises $37M to Commercialize Next Generation...

Genapsys, Inc. Raises $37M to Commercialize Next Generation Sequencing Platform

Nov 14 2013, 7:02am CST | by PR.com

Redwood City, CA, November 14, 2013 --(PR.com)-- GenapSys™, Inc. (GenapSys), a provider of Next Generation Sequencing (NGS) systems, today announced it has raised $37M to commercialize the GENIUS™ 110 system (Gene Electronic Nano-Integrated Ultra-Sensitive), a fully integrated DNA Sequencing system for the rapidly evolving NGS market.

The Series B financing includes new investors Yuri Milner, Stanford StartX Fund, and numerous private and institutional investors with life sciences expertise, alongside existing investors Decheng Capital and IPV Capital.

Dr. Esfandypour, GenapSys Founder and CEO, made the following statement: “The power of genomics is vast and far reaching – in our lifetime we will see genomics feed the world’s population through optimizing crop yield, we’ll see genomics ensure enhanced security through accurate identification, and we’ll see genomics elevate our understanding and knowledge about the world in which we live. I believe the revolutionary genomic solution that we have been developing at GenapSys will generate a quantum leap forward to a better, more informed and healthier future. With this financing and the strong backing of our investors, we now have all the pieces in place to deliver on the commercial promise of the GENIUS System and realize a 100x improvement in cost and efficacy as compared to existing technologies on the market.

About GenapSys Inc.
GenapSys, headquartered in Redwood City, CA, is a venture backed privately-held company that has created, developed and is producing a market disrupting Genomic Testing system. GenapSys’s advisory board includes among others, Ron Davis, Director of Stanford Genome Technology Center, George Church, Professor of Genetics at Harvard Medical School, Eric Topol, Director of the Scripps Translational Science Institute, and Mike Snyder, Director of Stanford Center for Genomics and Personalized Medicine. The company’s first product, the GENIUS™ 110 System, will enable customers to replace an expensive and time-consuming sample preparation and sequencing bottleneck with a streamlined workflow for Next Generation Sequencing. Its patented GENIUS system integrates advanced fluidics and analytical capabilities to produce sample-to-answer performance for DNA and RNA sequencing, while dramatically reducing capital and operating expenses. For more information, visit www.GenapSys.com.

Contact Information:
Genapsys Inc.
Howard Goldstein
Contact via Email

Read the full story here: http://www.pr.com/press-release/527762

Press Release Distributed by PR.com

Source: PR.com


blog comments powered by Disqus

Latest stories

15 Million T-Mobile User Data Stolen on Experian Servers
15 Million T-Mobile User Data Stolen on Experian Servers
Credit monitoring firm Experian has been hacked. Affected are about 15 million T-Mobile Customers. T-Mobile CEO John Legere responds.
Narendra Modi Courts Silicon Valley Companies, Making India the New China
Narendra Modi Courts Silicon Valley Companies, Making India the New China
India’s prime minister, Narendra Modi, is courting the top technology companies in Silicon Valley. On Saturday, Mr. Modi visited Tesla and met Elon Musk. He also had dinner with Microsoft CEO Satya Nadella and Google...
How Can Solar Panels Be Made More Efficient?
How Can Solar Panels Be Made More Efficient?
The unique Kirigami technique can help capture more sunlight as it enables solar panel cells to track the sun throughout the day.
Amazon Christmas 2015 Rumor - Smallest Tablet Ever?
Amazon Christmas 2015 Rumor - Smallest Tablet Ever?
With Labor Day having come and gone, Christmas is starting to roll out into stores and onto the internet - and everyone is trying to get a head start on the competition. Amazon is one of the first to have rumors come...